Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis

Completed · Phase 2 · Has a placebo group

Conditions studied: Psoriasis

In brief

This was a multicenter, randomized, vehicle-controlled, double-blind parallel group study to evaluate the efficacy and safety of CD 2027 Oily Spray applied twice daily for 8 weeks in participants with plaque-type psoriasis.

Key facts

Study ID

NCT00763555

Run by

Galderma R&D

People needed

88

Starts

2008-09-01

Expected to finish

2009-03-01

Last updated by the study team

2022-08-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant has a diagnosis of plaque-type psoriasis up to 20% of body surface area (BSA) involved excluding the scalp, with a Global Severity Score of at least 3 (moderate) at Screening
• Participant presents with a representative target lesion that is at least 16 cm² in area, is located on the non-bony areas of the skin, has a Scaling Score up to 2 (moderate), has a DSS of at least 4

You may not qualify if…

• Other type of psoriasis (other than plaque)
• Significant abnormal lab findings
• Hypercalcemia

Where it is running

• Minnesota Clinical Study Center — Fridley, Minnesota, United States
• Tennessee Clinical Research Center — Nashville, Tennessee, United States
• Stratica Medical — Edmonton, Alberta, Canada
• Ultranova Skincare — Barrie, Ontario, Canada
• North Bay Dermatology Centre — North Bay, Ontario, Canada
• K. Papp Clinical Research, Inc. — Waterloo, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.